Ancora Heart Appoints Mark Miles as Chief Commercial Officer

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Ancora Heart, Inc. , a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO).

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, June 23, 2022
Information
Tags: 
Health, Medical Devices, Cardiology, Eli Lilly and Company, Mile, Eli Lilly, James Madison University, Business administration, Safety, IPO, Regulation of tobacco by the U.S. Food and Drug Administration, Medtronic, CEO, Life expectancy, Company, Leadership, Adoption, Bachelor, LinkedIn, Growth, Heart failure, Marketing, Quality of life, Food, Patient, LVAD, Pepperdine University, PMA, CCO, HF, Pharmaceutical industry, Medical device, Heart, Facebook
Geotags: 
CALIFORNIA, UNITED STATES, NORTH AMERICA
⚠ generated by AI ↴
Organisation: 
THE ACCUCINCH® VENTRICULAR RESTORATION SYSTEM, ANCORA HEART
Summary
Key Points: 
  • Ancora Heart, Inc. , a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO).
  • View the full release here: https://www.businesswire.com/news/home/20220623005394/en/
    Mark Miles joins Ancora Heart as Chief Commercial Officer (Photo: Business Wire)
    Marks track record in commercialization and marketing of groundbreaking medical device therapies adds an important dimension of expertise to the Ancora Heart team, said Jeff Closs, president and CEO of Ancora Heart.
  • Im honored to be joining Ancora Heart as chief commercial officer, especially at this stage in the companys development, said Miles.
  • Miles brings 25 years of experience scaling medical technology companies to Ancora Heart, including his most recent post as CCO of Terumo Aortic.


Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO). He will oversee commercialization strategy for the AccuCinch® Ventricular Restoration System, the only completely transcatheter procedure to treat the enlarged left ventricle for patients with symptomatic heart failure and a reduced ejection fraction (HFrEF), currently being evaluated in the CORCINCH-HF pivotal clinical trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005394/en/

Mark Miles joins Ancora Heart as Chief Commercial Officer (Photo: Business Wire)

Mark Miles joins Ancora Heart as Chief Commercial Officer (Photo: Business Wire)

“Mark’s track record in commercialization and marketing of groundbreaking medical device therapies adds an important dimension of expertise to the Ancora Heart team,” said Jeff Closs, president and CEO of Ancora Heart. “While we are currently focused on enrollment in our pivotal trial, we also recognize the importance of looking forward with an ultimate goal of transitioning from clinical to commercial-stage, and we are thrilled to have Mark on board to drive this strategy.”

A fundamentally different and innovative device-based therapy, the AccuCinch System is designed to improve the structure and function of the heart and help bring relief to patients with heart failure who remain symptomatic despite current guideline-directed medical care.

“I’m honored to be joining Ancora Heart as chief commercial officer, especially at this stage in the company’s development,” said Miles. “Ancora Heart’s innovative AccuCinch technology uniquely fills an important treatment gap for HFrEF patients, and I look forward to helping the Ancora Heart team establish a foundation for this tremendous opportunity in the continuum of heart failure care.”

Miles brings 25 years of experience scaling medical technology companies to Ancora Heart, including his most recent post as CCO of Terumo Aortic. In that role, he was responsible for global sales and marketing, custom solutions, portfolio strategy and expansion into new markets, helping guide the company during a period of significant growth.

Prior to his time at Terumo Aortic, Miles served as senior director of commercial strategy at Invuity, where he played a key role in driving adoption of their core product lines across key surgical specialties throughout the United States. He was instrumental in facilitating significant growth through the company’s eventual IPO in 2015. Previously, Miles held positions of increasing responsibility at Medtronic, serving as director of global marketing of the Endovascular Business Unit. He began his career at Eli Lilly and Company, serving various commercial leadership roles during his eight-year tenure. Miles received a Master of Business Administration from Pepperdine University and Bachelor of Science degree in health sciences from James Madison University.

About the AccuCinch® Ventricular Restoration System

The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure (HF) patients. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant.

During the minimally invasive transcatheter AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. By directly treating the left ventricle, the AccuCinch System may help reduce symptoms, improve quality of life and potentially increase life expectancy.

The CORCINCH-HF pivotal trial is underway, designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in patients who have symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). (ClinicalTrials.gov Identifier: NCT04331769). This study is being conducted to support the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration.

About Ancora Heart

Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company’s proprietary AccuCinch® Ventricular Restoration System is the only completely transcatheter device designed to restore the structure and function of the enlarged left ventricle of the heart, thereby addressing the fundamental issue in the progression of heart failure in patients with reduced ejection fraction (HFrEF). Ancora Heart is a privately held company located in Santa Clara, Calif. For more information, please visit www.ancoraheart.com and connect on Twitter (@AncoraHeart), LinkedIn and Facebook.

Copyright: 
Copyright Business Wire 2022